• 제목/요약/키워드: Metastases of hepatocellular carcinoma

검색결과 27건 처리시간 0.027초

간세포암의 기관지내 전이 (Endobronchial Metastases of Hepatocellular Carcinoma)

  • 하근우;강풍;최효진;주미;진성림;진재용;이혁표;최수전;염호기
    • Tuberculosis and Respiratory Diseases
    • /
    • 제51권4호
    • /
    • pp.386-389
    • /
    • 2001
  • An endobronchial metastasis is defined as a subsegmental or a more proximal central bronchial metastasis of a nonpulmonary neoplasm in the bronchoscopically visible range. However, the frequencies of endobronchial metastasis range from 2 to 50% of pulmonary metastases from extrathoracic neoplasms by a different definition of an endobronchial metastasis. Primary neoplasms of an endobronchial metastasis including breast cancer, colon cancer, renal cell carcinoma, and ovarian cancer are relatively common. However, an endobronchial metastasis arising from thyroid cancer, parotid gland tumor, bone tumor, bladder cancer, and stomach cancer has only rarely been reported in the literature. Here we report a case of an endobrochial metastases from a hepatocellular carcinoma.

  • PDF

간세포암에서 $^{18}F-FDG$ PET의 임상 이용 (Clinical Application of $^{18}F-FDG$ PET in Hepatocellular Carcinoma)

  • 오소원;김석기
    • Nuclear Medicine and Molecular Imaging
    • /
    • 제42권sup1호
    • /
    • pp.60-65
    • /
    • 2008
  • Hepatocellular carcinoma is the most common primary tumor in the liver. FDG PET has been applied for staging and treatment planning of hepatocellular carcinoma. It could reflect tumor prognosis because glucose metabolism assessed by FDG PET is known to have correlations with the differentiation and aggressiveness of the tumor. Although the ability of FDG PET to detect well-differentiated or low grade tumors and intra-hepatic lesions is not good, it is expected to playa major role in pre-surgical assessments for liver transplantation because it is useful in detecting extra-hepatic lesions and unexpected distant metastases with a better diagnostic performance than other conventional imaging modalities. Additionally, FDG PET has an advantage to screen other cancers through whole body scanning. As a new tracer for PET, Acetate demonstrates higher sensitivity and specificity to FDG in evaluating hepatocellular carcinoma. It thus seems that simultaneous use of Acetate PET with FDG PET could be helpful in diagnosis, especially detecting extra-hepatic metastases.

$^{99m}Tc-HIDA$를 이용(利用)한 원발성간세포암전이(原發性肝細胞癌轉移) 병소(病巢)의 진단(診斷) (Detection of Metastases of Primary Hepatocellular Carcinoma with $^{99m}Tc-HIDA$ Scintigraphy)

  • 홍기석;홍성운;이진오;강태웅;허대석
    • 대한핵의학회지
    • /
    • 제17권1호
    • /
    • pp.85-87
    • /
    • 1983
  • $^{99m}Tc-Sulfur$ Colloid is concentrated in Kupffer cells of the liver, whereas the new biliary agents such as $^{99m}Tc-HIDA$ are processed by hepatic parenchymal cells. The distant metastatic lesiors in skull and lung of the primary hepatocellular carcinoma in 38-year old Korean male were detected with $^{99m}Tc-HIDA$ scintigraphy. The chest PA, skull bone X-ray and radionuclide scintigraphic studies are illustrated. This observation suggests that $^{99m}Tc-HIDA$ scintigraphy is useful for detection of distant metastases of primary hepatocellular carcinoma.

  • PDF

Clinical outcomes of stereotactic body radiotherapy for spinal metastases from hepatocellular carcinoma

  • Lee, Eonju;Kim, Tae Gyu;Park, Hee Chul;Yu, Jeong Il;Lim, Do Hoon;Nam, Heerim;Lee, Hyebin;Lee, Joon Hyeok
    • Radiation Oncology Journal
    • /
    • 제33권3호
    • /
    • pp.217-225
    • /
    • 2015
  • Purpose: To investigate the outcomes of patients with spinal metastases from hepatocellular carcinoma (HCC), who were treated by stereotactic body radiotherapy (SBRT). Materials and Methods: This retrospective study evaluated 23 patients who underwent SBRT from October 2008 to August 2012 for 36 spinal metastases from HCC. SBRT consisted of approximately 2 fractionation schedules, which were 18 to 40 Gy in 1 to 4 fractions for group A lesions (n = 15) and 50 Gy in 10 fractions for group B lesions (n = 21). Results: The median follow-up period was 7 months (range, 2 to 16 months). Seven patients developed grade 1 or 2 gastrointestinal toxicity, and one developed grade 2 leucopenia. Compression fractures occurred in association with 25% of the lesions, with a median time to fracture of 2 months. Pain relief occurred in 92.3% and 68.4% of group A and B lesions, respectively. Radiologic response (complete and partial response) occurred in 80.0% and 61.9% of group A and B lesions, respectively. The estimated 1-year spinal-tumor progression-free survival rate was 78.5%. The median overall survival period and 1-year overall survival rate were 9 months (range, 2 to 16 months) and 25.7%, respectively. Conclusion: SBRT for spinal metastases from HCC is well tolerated and effective at providing pain relief and radiologic response. Because compression fractures develop at a high rate following SBRT for spinal metastases from primary HCC, careful follow up of the patient is required.

Post-treatment intracranial hemorrhage of brain metastases from hepatocellular carcinoma

  • Kim, Kyung Su;Kim, Kyubo;Chie, Eui Kyu;Kim, Yoon Jun;Yoon, Jung Hwan;Lee, Hyo-Suk;Ha, Sung W.
    • Radiation Oncology Journal
    • /
    • 제33권1호
    • /
    • pp.36-41
    • /
    • 2015
  • Purpose: To evaluate the incidence and risk factors of post-treatment intracranial hemorrhage of brain metastases from hepatocellular carcinoma (HCC). Materials and Methods: Medical records of 81 patients who have been diagnosed of brain metastases from HCC and underwent surgery, radiosurgery and/or whole brain radiotherapy (WBRT) between January 2000 and December 2013 were retrospectively reviewed. Results: Intracranial hemorrhage was present in 64 patients (79%) at the time of diagnosis. Median value of alpha-fetoprotein (AFP) level was 1,700 ng/mL. The Eastern Cooperative Oncology Group (ECOG) performance status for 20 patients was greater than 2. Fifty-seven patients underwent WBRT and the others were treated with surgery and/or radiosurgery without WBRT. During follow-up, 12 events of intracranial hemorrhage after treatment were identified. Three-month post-treatment hemorrhage rate was 16.1%. Multivariate analyses revealed that ECOG performance status, AFP, and WBRT were associated with post-treatment hemorrhage (p = 0.013, 0.013, and 0.003, respectively). Kaplan-Meier analysis showed that 3-month post-treatment hemorrhage rate of new lesion was higher in patients treated without WBRT, although statistical significance was not reached. (18.6% vs. 4.6%; p = 0.104). Ten of 12 patients with post-treatment hemorrhage died with neurologic cause. Conclusion: WBRT should be considered to prevent post-treatment hemorrhage in the treatment of brain metastases from HCC.

Prognostic factors in hepatocellular carcinoma patients with bone metastases

  • Kim, Sungmin;Choi, Youngmin;Kwak, Dong-Won;Lee, Hyung Sik;Hur, Won-Joo;Baek, Yang Hyun;Lee, Sung Wook
    • Radiation Oncology Journal
    • /
    • 제37권3호
    • /
    • pp.207-214
    • /
    • 2019
  • Purpose: To identify the prognostic factors that could influence survival and to compare prognoses of the patients with the number of the risk factors that might assist in the adequate management of hepatocellular carcinoma (HCC) patients with bone metastases that showed a heterogeneous range of survival. Materials and Methods: A total of 41 patients, treated with radiotherapy (RT) for bone metastases from HCC from 2014 to 2017, were enrolled retrospectively. Survival was determined by the Kaplan-Meier method from the start of the RT for metastatic bone lesions. Pre-RT clinical features were evaluated and their influences on survival were analyzed. The significant factors were considered to compare survivals according to the number of prognostic factors. Results: Median follow-up was 6.0 months (range, 0.5 to 47.0 months). The median overall survival was 6.5 months, and the 1-year and 2-year survival rates were 35.5% and 13.5%, respectively. Multivariate analysis revealed that the Child-Pugh class A group, alpha-fetoprotein increased more than 30 ng/mL, and HCC size of more than 5 cm were associated with worse overall survival. The median survivals in HCC with none, 1, 2, and 3 of the aforementioned risk factors were 19.5, 9.0, 2.5, and 1.0 months, respectively (p < 0.05). Conclusion: Our results show that the overall survivals were significantly different according to the number of the risk factors among HCC patients with bone metastases who showed various lengths of survival.

Survival-Related Factors of Spinal Metastasis with Hepatocellular Carcinoma in Current Surgical Treatment Modalities : A Single Institute Experience

  • Lee, Min Ho;Lee, Sun-Ho;Kim, Eun-Sang;Eoh, Whan;Chung, Sung-Soo;Lee, Chong-Suh
    • Journal of Korean Neurosurgical Society
    • /
    • 제58권5호
    • /
    • pp.448-453
    • /
    • 2015
  • Objective : Recently, the survival of patients with hepatocellular carcinoma (HCC) has been prolonged with improvements in various diagnostic tools and medical treatment modalities. Consequently, spine metastases from HCC are being diagnosed more frequently. The accurate prediction of prognosis plays a critical role in determining a patient's treatment plan, including surgery for patients with spinal metastases of HCC. We investigated the clinical features, surgical outcomes, and prognostic factors of HCC presenting with spine metastases, in patients who underwent surgery. Methods : A retrospective review was conducted on 33 HCC patients who underwent 36 operations (three patients underwent surgical treatment twice) from February 2006 to December 2013. The median age of the patients was 56 years old (range, 28 to 71; male : female=30 : 3). Results : Overall survival was not correlated with age, sex, level of metastases, preoperative Child-Pugh classification, preoperative ambulatory function, preoperative radiotherapy, type of operation, administration of Sorafenib, or the Tokuhashi scoring system. Only the Tomita scoring system was shown to be an independent prognostic factor for overall survival. Comparing the Child-Pugh classification and ambulatory ability, there were no statistically differences between patients pre- and post-operatively. Conclusion : The Tomita scoring system represents a practicable and highly predictive prognostic tool. Even though surgical intervention may not restore ambulatory function, it should be considered to prevent deterioration of the patient's overall condition. Additionally, aggressive management may be needed if there is any ambulatory ability remaining.

원발성 종양의 증거 없이 발생한 간세포암종의 흉벽 전이 -1예 보고- (Chest Wall Metastasis from Unknown Primary Hepatocellular Carcinoma -A case report -)

  • 김혁;양주민;강정호;김영학;정원상;전순호
    • Journal of Chest Surgery
    • /
    • 제37권9호
    • /
    • pp.809-812
    • /
    • 2004
  • 흉벽에 발생하는 전이성 악성 종양은 드문 질환이며 주위 장기로부터 전이되는 경우가 대부분으로 유방, 폐, 흉막, 그리고 종격동 등으로부터 주로 전이되는 것으로 알려져 있다. 특히 흉부가 아닌 먼장기로부터 전이되는 경우는 더욱 드문 것으로 알려져 있고 원발성 악성 종양이 없이 흉벽 전이에 의해 발현되는 예는 몇몇의 보고만이 있을 뿐이다. 환자는 51세 남자로 전흉벽 좌상부에 촉지되는 종괴로 절제 수술을 시행 후 전이성 간세포암종으로 진단 받았고 당시 검사상 간에 원발성 간세포암종의 증거는 없는 상태였다. 이에 원발성 종양의 증거 없이 간세포암이 흉벽으로 전이된 예를 치험하였기에 보고하는 바이다.

A patient who has survived for a long period with repeated radiotherapies for multifocal extrahepatic metastases from hepatocellular carcinoma

  • Jo, Sunmi;Shim, Hye Kyung
    • Radiation Oncology Journal
    • /
    • 제31권4호
    • /
    • pp.267-272
    • /
    • 2013
  • Although significant advances in the treatment of intrahepatic lesions, it is reported that the prognosis for patients with hepatocellular carcinoma (HCC) who have extrahepatic metastasis remains poor. We report a patient with lung, liver, brain, bone and subcutaneous metastasis from HCC who has survived more than 7 years maintaining relatively good performance status as a result of repeated therapies. A 55-year-old male patient with HCC underwent right lobectomy of the liver and cholecystectomy in September 2006. He received wedge resection for lung metastasis twice (July 2009, January 2011) and Gamma Knife stereotactic radiosurgery for brain metastasis (April 2011). Over the last 3 years, he has developed metastasis in subcutaneous tissues, muscle, and bone with pain. He has undergone 7 courses of radiotherapies for subcutaneous tissues, muscle, and bone metastasis and been prescribed sorafenib and he is still capable of all self-care.

Little Response of Cerebral Metastasis from Hepatocellular Carcinoma to Any Treatments

  • Han, Jung-Ho;Kim, Dong-Gyu;Park, Jung-Cheol;Chung, Hyun-Tai;Paek, Sun-Ha;Chung, Young-Seob
    • Journal of Korean Neurosurgical Society
    • /
    • 제47권5호
    • /
    • pp.325-331
    • /
    • 2010
  • Objective : We retrospectively evaluated the survival outcome of patients with brain metastasis from hepatocellular carcinoma (HCC). Methods : Between 1991 and 2007, a total of 20 patients were diagnosed as having brain metastasis from HCC. The mean age of the patients was 55 ${\pm}$ 13 years, and 17 (85.0%) were men. Seventeen (85.0%) patients had already extracranial metastases. The median time from diagnosis of HCC to brain metastasis was 18.5 months. Fourteen (70.0%) patients had stroke-like presentation due to intracerebral hemorrhage (ICH). Ten (50.0%) patients had single or solitary brain metastasis. Among a total of 34 brain lesions, 31 (91.2%) lesions had the hemorrhagic components. Results : The median survival time was 8 weeks (95% CI, 5.08-10.92), and the actuarial survival rates were 85.0%, 45.0%, 22.5%, and 8.4% at 4, 12, 24, and 54 weeks. Age < 60 years, treatment of the primary and/or extracranial lesions, and recurrent ICH were the possible prognostic factors (p = 0.044, p < 0.001, and p = 0.111, respectively). The median progression-free survival (PFS) time was 3 months (95% CI, 0.95-5.05). Conclusion : The overall survival of the patients with brain metastasis from HCC was very poor with median survival time being only 8 weeks. However, the younger patients less than 60 years and/or no extracranial metastases seem to be a positive prognostic factor.